During postpartum hemorrhage, a fibrinogen level below 2 g/L can change what you ask the blood bank to send. The decision is not a universal yes/no tied to massive hemorrhage protocol activation, and it is not to wait for every test before responding. Check fibrinogen early, use results to guide targeted replacement when available, and follow the local hemorrhage protocol for any specified empiric products while results are pending. Continue source control in parallel. This article focuses on postpartum hemorrhage; severe antepartum bleeding may require a cause-specific pathway.
Why fibrinogen can fall early
Fibrinogen is the building block that becomes fibrin, which helps stabilize a clot. Levels are normally higher in late pregnancy than outside pregnancy, providing a reserve. With severe ongoing bleeding, fibrinogen can be consumed and diluted by fluid and blood-product replacement; a low result is associated with progression to severe hemorrhage.
That makes fibrinogen useful as an early warning about hemostatic capacity—not as a diagnosis of the bleeding source. A low level does not tell you whether the cause is atony, retained tissue, trauma, abruption, or a coagulation disorder. A level above the replacement threshold does not make ongoing blood loss safe or rule out another problem.
Let the result change the product, not the urgency
In active postpartum hemorrhage, fibrinogen below 2 g/L is a commonly used trigger for replacement. The World Health Organization’s 2025 guidance recommends cryoprecipitate when fibrinogen is below this level, aiming for at least 2 g/L. Think of 2 g/L as a treatment threshold in ongoing hemorrhage—not a definition of postpartum hemorrhage, a measure of blood loss, or a reason to stop assessing the patient.
Send fibrinogen early alongside the other tests in your local hemorrhage pathway, and repeat it if bleeding continues or after substantial replacement. Where available, a locally validated viscoelastic assay can help assess clot formation more quickly; its thresholds depend on the assay and local algorithm, so do not treat a value from one device as automatically interchangeable with another.
| Finding during ongoing PPH | What it changes | What it does not mean |
|---|---|---|
| Fibrinogen <2 g/L | Supports fibrinogen replacement under the local protocol; WHO recommends cryoprecipitate to reach at least 2 g/L. | It does not identify the cause of bleeding or replace surgery or other source control. |
| Fibrinogen ≥2 g/L | Does not meet the <2 g/L laboratory trigger for targeted replacement by itself; interpret it with the clinical course, other tests, and local algorithm. | It does not rule out hemorrhage, another coagulation problem, or deterioration. |
| Result delayed while bleeding escalates | Continue resuscitation and definitive management under the local protocol; contact the blood bank about product availability. Use protocol-directed empiric support when indicated. | It is not a reason to wait to move to the operating theater when source control is needed. |
Replace a deficit while following the emergency protocol
When replacement is indicated by the measured result or local empiric pathway, use the product available through your institution’s protocol—typically cryoprecipitate or fibrinogen concentrate. WHO estimates that reaching its target typically requires 3–4 g of fibrinogen, corresponding to about 8–10 units of cryoprecipitate; actual content, pooling conventions, and dosing instructions vary. Confirm the order with the transfusion service and follow the local plan for reassessment.
Plasma supplies fibrinogen, but it is not as concentrated or predictable a way to correct an isolated fibrinogen deficit. Massive transfusion protocols may use empiric component ratios while results are pending, and some obstetric packs also include cryoprecipitate or fibrinogen concentrate. Protocols differ. A ratio—including 1:1:1—should not be mistaken for proof that fibrinogen has been restored; use the measured or locally assessed deficit to guide targeted replacement when results are available.
There is evidence against a routine fixed preemptive dose of fibrinogen concentrate for every patient with postpartum hemorrhage. In a randomized trial of severe PPH, the mean fibrinogen level at enrollment was 4.5 g/L, and a fixed early dose did not reduce red-cell transfusion. This supports avoiding routine fixed dosing in patients without demonstrated deficiency. It does not settle whether a local protocol should issue empiric fibrinogen products for severe ongoing bleeding with suspected coagulopathy while tests are delayed, and it does not argue against replacing documented hypofibrinogenemia.
Keep replacement and source control moving together
Fibrinogen helps the patient form clots; it does not make the uterus contract, remove retained tissue, repair a laceration, or control bleeding from an operative source. If the clinical picture calls for the operating theater, do not delay transfer while waiting for a fibrinogen result or a laboratory target. Resuscitation, targeted correction, and definitive control of the bleeding can proceed in parallel.
During transfer, make the handoff useful: communicate the latest fibrinogen result and when it was drawn, whether it is falling, what fibrinogen product has been ordered or given, when additional product is expected, and whether bleeding or perfusion has changed. That turns a laboratory value into an actionable plan for the operating-room team.
Practical takeaways
- In ongoing postpartum hemorrhage, fibrinogen below 2 g/L is a trigger for targeted replacement under current WHO guidance; aim for at least 2 g/L.
- Check fibrinogen early and reassess when bleeding continues; a normal result does not rule out dangerous hemorrhage.
- MTP packs vary: some local protocols include empiric fibrinogen products while results are pending. A component ratio alone does not show that fibrinogen has been corrected, and routine fixed preemptive concentrate dosing for everyone is unsupported.
- Cryoprecipitate or fibrinogen concentrate supports clot formation but never replaces source control or timely transfer.
